Global

‡ In these countries please contact our distributor

DURAFIBER

Høyabsorberende geldannende fiberbandasje

DURAFIBER Gelling Fibre Dressing Range

Produkt informasjon

DURAFIBER består av en ny generasjon sterke, geldannende fiberbandasjer som enkelt kan fjernes i ett stykke.1-6

 

DURAFIBER, half wet, half dryHøy ytelse

DURAFIBER har høy ytelse, og er designet for å møte de mange utfordringene med middels og sterkt væskende infiserte og ikke-infiserte sår.

DURAFIBER er utviklet med innovativ fiberteknologi, og med en unik, uvevd fiberblanding som er spesielt avgjørende for bandasjens høye ytelse. 

Den unike blandingen gir dermed en eksklusiv kombinasjon av fordeler som skiller DURAFIBER fra tradisjonelle geldannende fibebandasjer.

Ren fjerning i ett stykke1-6

DURAFIBER Clean one piece removalHøy våtfasthet og strukturell integitet1-6 

  • Lav risiko for fiberrakning og bandasjerester3,5
  • Pasienten opplever minimal smerte og traume ved fjerning og skift1-6

Video om DURAFIBER bandasjeteknologi

 

Effektiv sårvæske kontroll

DURAFIBER Locking In Video StillHøy absorberingsevne og oppbevaringskapasitet1,2,4,9

  • Minimal lekkasje– bidrar til å beskytte kantene av såret mot risiko for maserasjon2,3,5,8,11  
  • Låser inn væske og skadelige bakterier – kan bidra til å forhindre risikoen for krysskontaminering ved fjerning1,2,4,7-10,12,13

Video med testing av siving mot siden

Dette in vitro-eksperimentet illustrerer DURAFIBER bandasjens evne til å låse inn absorbert væske og på den måten kontrollere spredningen av sårvæske. 1,2,8 

Når DURAFIBER er lagt på, spres væsken raskt bort fra overflaten av petri-skålen (som representerer væskingen i sårbunnen). Den absorberte væsken spres ikke til de ytre kantene av bandasjen, men beholdes innenfor området av den simulerte sårbunnen. 

Bandasjens evne til å kontrollere spredningen av væsken til siden, er viktig ved at den minimerer risikoen for maserasjon rundt kanten av såret. . 1,2,8



Video med sperretest

Dette in vitro-eksperimentet bruker væske med forskjellige farger til å illustrere DURAFIBER bandasjens evne til å sperre av for væsken den absorberer med det resultatet at fargene ikke smitter over i hverandre1,2,7.



Kompromissløs komfort for pasienten3,5

DURAFIBER conforming gelSkånsom, komfortabel gelmatrise1,2,5,19  

  • Bidrar til samarbeid fra pasientens side3,5
  • Reduserer hulrom der bakterier kan spre seg1,2,12,19,20

Video med kontakt test

Dette in vitro-eksperimentet viser hvordan DURAFIBER bandasjen raskt forvandles til en myk, sammenhengende gel idet den kommer i kontakt med væske, og legger seg tett mot den simulerte sårbunnen. Bandasjens evne til legge seg tett mot sårflaten uten å klistre seg fast, er sentral i å bidra til å opprettholde et fuktig sårmiljø, noe som er gunstig for tilheling.

 



Sikker effektivitet

Unike egenskaper som hindrer krymping1,2,4

  • Minimal krymping i våt tilstand – kan bidra til langvarig dekning1,2,4
  • Opprettholder et gunstig miljø for sårtilheling1,18,21

 

Spesialdesignet med innovativ teknologi

Sortimentet av DURAFIBER bandasjer har en unik blanding av uvevd fiber som utgjør en vesentlig del av den høye ytelsen.

20%

 Naturlig styrkende cellulosefibre

+

80%

 Geldannende cellulose ethyl sulphonate fibres (CES)

=

100%

 En fint vevet matrise som danner en myk, sammenhengende gel ved kontakt med sårvæske1-6

DURAFIBER animation stillDenne unike blandingen gir en eksklusiv kombinasjon av egenskaper som gjør det mulig for DURAFIBER å møte de mange utfordringene ved væskende sår:

  • Sterk i kontakt med vann: Cellulosefibre gir den tørre gelmatrisen innebygd, strukturell integritet1-6
  • Enestående oppsugningsevne: Geldannende fibrer svulmer ved kontakt med sårvæske og absorberer og sperrer væsken inne1,2,4-6
  • Minimal krymping: Forsterkende fibre gjør at bandasjen beholder fasongen når den er våt, og minimerer krymping1,2,4
  • Meget føyelig: Forvandles til et mykt, bindekraftig gel-ark som former seg tett til sårbunnen1-3,5,10,14

DURAFIBER Produktinformasjon

DURAFIBER ALLEVYN Gentle Border Multisite
DURAFIBER ALLEVYN  Gentle Border Multisite

ALLEVYN bandasje - et ideelt valg for sekundær fiksering.28,30


DURAFIBER Ag bandasjer

DURAFIBER AgDURAFIBER Ag bandasjer er effektive mot infeksjon

Langvarig frigivelse av sølv i opptil 7 dager (in vitro14,15

Begynner å drepe patogener innen 30 minutter etter kontakt  (vises in vitro vs. Staphylocuccus aureus, Pseudomonas aeruginosa, MRSA og VRE)16

Gir et bredt spekter av antimikrobiell aktivitet ved 4 timer mot patogener (vises in vitro kontra

DURAFIBER AgPseudomonas aeruginosa, VRE, Bacteroides fragilisCandida albicans and Rhizopus arrhizus)17

Beskytter i opptil 7 dager mot et bredt spekter av aerobe, anaerobe bakterier, inkludert antibiotikaresistente stammer (vises in vitro kontra MRSA, VRE, sopp, trådformede soppsårpatogener)14,15

DURAFIBER Ag Produktinformasjon

 

Referanser

1 Smith & Nephew Report DS.10.056 R1 05 2010 DURAFIBER Dressing Physical Properties.

2 DS.11.187.DOF Testing Performed as Part of DURAFIBER Photo Shoot.

3 Case Series Evaluation: The Use of DURAFIBER on Exuding Wounds. Wounds UK 2012,Vol 8, No 3.

4 Smith & Nephew Wound Management Laboratory Report Reference DS/10/060/R1, DURAFIBER Ag Dressing Physical Properties, Dowler A, September 2010.

5 Smith & Nephew Wound Management, Data on File Report Reference OR- DOF/28, A prospective, open, multicentre study to evaluate a new fibrous silver dressing in the treatment of moderate to highly exuding chronic wounds, Rafiq G, Fenton S January 2013.

6 Smith & Nephew Wound Management Laboratory Report Reference DS/12/093/DOF, Integrity Testing of DURAFIBER Ag in horse serum and ionic solution, Dowler A, April 2012.

7 Smith & Nephew Wound Management Data on File 10.040.01 April 2010 Visual demonstration of sequestration of Pseudomonas aeruginosa and Staphylococcus aureus in a DURAFIBER dressing using confocal microscopy.

8 Smith & Nephew Report DS.10.042 R1 Report of testing on lateral wicking of DURAFIBER versus AquacelTM and Kaltostat TM dressings.

9 Smith & Nephew Wound Management Laboratory Report Reference DS/12/109/DOF, Testing on Absorption of DURAFIBER Ag versus Aquacel Ag during compression, Dowler A, April 2012.

10 Smith & Nephew Wound Management Laboratory Report Reference DS/12/158/DOF, Sequestration Testing of DURAFIBER Ag, Aquacel Ag and SorbsanTM Silver Flat, Dowler A,June 2012.

11 Smith & Nephew Wound Management Laboratory Report Reference DS/12/108/DOF, Testing on lateral wicking of DURAFIBER Ag versus Aquacel Ag and MaxorbTM Extra Ag dressings, Dowler A, April 2012.

12 Smith & Nephew Research Centre Review Report, The potential for proliferation of bacteria in wound exudate, Report Reference RR-WMP06290-40-01, Woodmansey E, April 2010.

13 Smith & Nephew Wound Management, Data on file report reference 1208007, Visual demonstration of sequestration of Pseudomonas aeruginosa and Staphylococcus aureus in a DURAFIBER Ag dressing using confocal microscopy. Lumb H, August 2012.

14 Smith & Nephew Wound Management, Data on file report reference 1004007, Antimicrobial activity of DURAFIBER Ag and Aquacel Ag against bacteria, yeast and fungi commonly found in wounds over a 7 day period, Woodmansey E, April 2010.

15 Smith & Nephew Wound Management, Data on file report reference 1009012, Antimicrobial activity of DURAFIBER Ag against bacteria, yeast and fungi commonly found in wounds over a 7 day period, Vaughan KL, McMillan J, Lumb H and Woodmansey E, September 2010.

16 Smith & Nephew Wound Management, Data on file report reference 1004009, Assessment of the contact kill activity of DURAFIBER Ag against common wound pathogens, Woodmansey E, April 2010.

17 Smith & Nephew Wound Management, Data on file report reference 1009013, Antimicrobial activity of DURAFIBER Ag against bacteria, yeast and fungi commonly found in wounds over a 4 hour period, Vaughan KL, McMillan J, Lumb H and Woodmansey E, September 2010.

18 World Union of Wound Healing Societies (WUWHS) Principles of best practice. Wound exudate and the role of dressings. A consensus document London MED Ltd. 2007.

19 Smith & Nephew Wound Management Laboratory Report Reference DS/12/143/DOF, Intimate Contact Testing of DURAFIBER Ag, Aquacel Ag and Sorbsan Silver Flat, Dowler A, June 2012.

20 Smith & Nephew Research Centre Review Report RR WMP06290-40-01 The potential for proliferation of bacteria in wound exudate.

21 The Clinical and Physical Properties of DURAFIBER Ag, the Moist Wound Environment and the Autolytic Debridement, Myers D, July 2012.

22 Smith & Nephew Report DS.10.013 R1 02 2010 Aquacel Dressing Physical Properties.

23 Smith & Nephew Wound Management Laboratory Report Reference DS/10/060/R2, Aquacel Ag Dressing Physical Properties.

24 NHS Drug Tariff August 2012 http://www.ppa.org.uk/ppa/edit_intro.htm

25 Unit costs of health and social care, Curtis, L. PSSRU: 2010.

26 Siddiqui AR, Bernstein JM (2010).

27 DURAFIBER Technology video

28 Smith & Nephew Report DS/12/314 R December 2012 Wound Model Testing of DURAFIBER with various secondary dressings

29 DURAFIBER SMTL report 3303 Wound Dressing Testing

30 Smith & Nephew Report Development Services, Analytical Report Reference DS/10/053/R1, Wound Model Testing of DURFAIBER Ag and Aquacel Ag dressings with various secondary dressings, Dowler A, August 2010.

*In comparison with standard Aquacel dressings, excludes Aquacel Ribbon with strengthening fibre and Aquacel Extra

**In comparison with standard Aquacel Ag dressings, excludes Aquacel Ag Ribbon with strengthening fibre and Aquacel Ag Extra

Aquacel is a trademark of Convatec

TM All trademarks acknowledged

Pasient fordeler

Introduksjon

DURAFIBER sortimentet er en ny generasjon høytabsorberende, geldannende fiberbandasjer med en innovativ, ny fiberteknologi og en unik fiberblanding.1,2,4,9

DURAFIBER bandasjer reagerer på kontakt med sårvæske ved å danne en myk, bindekraftig gel som raskt absorberer overflødig sårvæske, sperrer av for den absorberte sårvæsken og bakterier den kan inneholde, og legger seg tett inntil sårbunnen. 1,2,3-5,7,8,10,14

  • Høy våtfasthet og strukturell integritet – bandasjen tas lett av i ett stykke1-6
  • Høy absorberingsevne– effektiv væskekontroll1-6,9
  • Unike egenskaper som forhindrer krymping – optimal effektivitet ved forbinding1,2,4
  • Myk og formbar – kompromissløs komfort for pasienten1,2,3,5

The following in-vitro experiments clearly demonstrate the various properties associated with DURAFIBER's innovative dressing technology.

Please see below a brief description of each test together with a video clip showing the outcome.

Contact Test2 

This in vitro experiment shows how the DURAFIBER dressing rapidly transforms into a soft cohesive gel as it is hydrated with fluid and conforms intimately to the simulated wound bed. The ability of a dressing to maintain close contact with the wound surface without adhering is key in helping to maintain a moist wound environment favourable for healing. It also helps to minimise the risk of pooling; reduce the potential for dead space between the wound and dressing interface and minimise the potential for trauma on dressing removal 1,2,12

Locking In Test2 

This in vitro experiment uses different coloured fluids to illustrate the ability of DURAFIBER dressings to lock in the fluid it absorbs with the result that there is no bleeding of the colours into one another1,2,7.

The ability of a dressing to lock in fluid is important for helping to remove excess fluid and any harmful bacteria it contains away from the wound bed and may reduce the risk of cross contamination on dressing removal.

Lateral Wicking Test2 

This in vitro experiment illustrates the ability of DURAFIBER dressings to lock in absorbed fluid and so control the lateral spread of wound fluid. 1,2,8

Once applied, DURAFIBER rapidly wicks the fluid away from the surface of the petri dish, (representative of exudate in a wound bed). The absorbed fluid does not spread to the outer edges of the dressing but is contained within the area of the simulated wound bed.

The ability of a dressing to control the lateral spread of fluid is important in helping to minimise the risk of peri-wound maceration.

Absorbency and Shrinkage Test2 

This in vitro experiment demonstrates the ability of DURAFIBER dressings to absorb markedly more fluid and to shrink noticeably less compared to standard Aquacel™*1,2,15

Both DURAFIBER and Aquacel*1,2,15 dressings have 25ml of fluid added to them. The excess fluid that they haven't absorbed is measured and compared in a test tube. The shrinkage seen with each dressing is measured by comparing the original dry and gelled dressing size.

Dressing absorbency is important for ensuring effective fluid management and minimal dressing shrinkage is important for achieving sustained wound bed coverage. 

Dressing Integrity and Gelled Strength Test2 

This in vitro experiment demonstrates the markedly greater gelled strength and integrity of DURAFIBER dressings compared to Aquacel™*1,2,15.

Each dressing has fluid added to the middle of the dressing to simulate the absorption of dressing exudate. Weights are then attached to each dressing until breaking point is reached. The weight required to break the two dressings is measured and compared.

Dressing strength is important for ensuring one piece dressing removal and low risk of dressing residue.5

 

  DURAFIBER Dressings DURAFIBER Ag Dressings

High gelled strength and structural integrity for clean one piece removal1-6

“performed well and was very easy to remove and stayed in one piece3

“...was removed as a single piece, leaving no residue, in >95%  of removals5

Excellent absorbency for effective fluid management and minimal risk of peri-wound maceration 1-6,8,9,11

“demonstrated excellent fluid handling properties and was effective at managing the wound exudate3

“was rated as clinically acceptable for exudate handling at 95.8% of assessments5

Minimal dressing shrinkage for sustained coverage and optimal dressing efficiencies 1,2,4

 “continued to demonstrate very good ability to conform to the wound bed3

“the mean patient dressing wear time was 6.4 days5

Soft and highly conformable for uncompromised patient comfort 1,2,3,5

“patient comfort was found to be excellent3

“Comfortable during wear at 94.8% of assessments5” 

 

DURAFIBER Clinical Evidence

Author Title Outcome  
Barrett S
Callaghan R
Ivins N
Stephen -Haynes J
Case series evaluation:
the use of Durafiber on
exuding wounds
Simon Barrett, Rosie Callaghan, Nicky Ivins and Professor Jackie Stephen-Haynes have completed a case series evaluating the use of the new DURAFIBER(Smith&Nephew) dressing on a total of ten patients with a range of wound aetiologies.

The case studies showed that DURAFIBER has the capability to contain high levels of exudate, provide comfort for patients during wear, and on removal as a result of its unique gelled structure and ability to remain intact.

PDF
(1.5MB)

 

 

Author Title Outcome  
Milne J A clinical evaluation of DURAFIBER, a new generation of fibrous gelling dressings "The majority of clinicians rated the performance of DURAFIBER as being either excellent or very good" for ease of dressing application, exudate handling ability, dressing conformability and ease of dressing removal. PDF (122 KB)

 

Evidence Graph

 

Summary of clinician feedback on DURAFIBER in-use performance

 

Case Study

Author Title Outcome  

Murray S, Pardoe A.

Case study of DURAFIBER on a dehisced surgical wound

DURAFIBER in situDURAFIBER achieved “complete healing in four weeks” with the ileostomy reversed.

 

DURAFIBER in situ

PDF (1.4MB)

 

 

Case Study

Author Title Outcome  

Grothier L

A case study illustrating the clinical benefits of using a fibrous gelling dressing

The “wound exudate had been managed effectively being contained within the DURAFIBER dressing with no shrinkage observed.”

PDF (412 KB)

 

 

DURAFIBER Ag

A prospective, open, multi centre study to evaluate a new fibrous silver dressing in the treatment of moderate to highly exuding chronic wounds5.

Ease of Use Graph

Ease of Use

  • The fibrous silver dressing Rated as clinically acceptable for the indication in 100% of patients     
  • Clinicians satisfied with the exudate handling of the fibrous silver dressing in 95.8% of the assessments
  • Easy to apply at 100% of assessments
  • Removed as a single piece in 96.8% of removals
  • No pain on application at 95.8% of assessments
  • No pain on removal at 88.4% of assessments
  • Mean wear time of 6.4 Days

 

Clinical Outcomes

Graph
50% of wounds healed by week 8

 

Graph

There was significant evidence of a reduction in the presence of clinical wound infection between baseline and weeks 4 (p<0.001) and week 8 (p<0.001).

 

Graph

There was also significant evidence of a reduction in the presence of clinical signs of infection between baseline and weeks 4 (p=0.002) and 8 (p<0.001).

 

Graph

The median percentage reduction in wound dimensions between baseline and study completion and the resulting median percentage reduction per week were as follows: Area 98.2% (12.9% per week), Depth 100% (12.7% per week) 

 

Referanser

1 Smith & Nephew Report DS.10.056 R1 05 2010 DURAFIBER Dressing Physical Properties.

2 DS.11.187.DOF Testing Performed as Part of DURAFIBER Photo Shoot.

3 Case Series Evaluation: The Use of DURAFIBER on Exuding Wounds. Wounds UK 2012,Vol 8, No 3.

4 Smith & Nephew Wound Management Laboratory Report Reference DS/10/060/R1, DURAFIBER Ag Dressing Physical Properties, Dowler A, September 2010.

5 Smith & Nephew Wound Management, Data on File Report Reference OR- DOF/28, A prospective, open, multicentre study to evaluate a new fibrous silver dressing in the treatment of moderate to highly exuding chronic wounds, Rafiq G, Fenton S January 2013.

6 Smith & Nephew Wound Management Laboratory Report Reference DS/12/093/DOF, Integrity Testing of DURAFIBER Ag in horse serum and ionic solution, Dowler A, April 2012.

7 Smith & Nephew Wound Management Data on File 10.040.01 April 2010 Visual demonstration of sequestration of Pseudomonas aeruginosa and Staphylococcus aureus in a DURAFIBER dressing using confocal microscopy.

8 Smith & Nephew Report DS.10.042 R1 Report of testing on lateral wicking of DURAFIBER versus AquacelTM and Kaltostat TM dressings.

9 Smith & Nephew Wound Management Laboratory Report Reference DS/12/109/DOF, Testing on Absorption of DURAFIBER Ag versus Aquacel Ag during compression, Dowler A, April 2012.

10 Smith & Nephew Wound Management Laboratory Report Reference DS/12/158/DOF, Sequestration Testing of DURAFIBER Ag, Aquacel Ag and SorbsanTM Silver Flat, Dowler A,June 2012.

11 Smith & Nephew Wound Management Laboratory Report Reference DS/12/108/DOF, Testing on lateral wicking of DURAFIBER Ag versus Aquacel Ag and MaxorbTM Extra Ag dressings, Dowler A, April 2012.

12 Smith & Nephew Research Centre Review Report, The potential for proliferation of bacteria in wound exudate, Report Reference RR-WMP06290-40-01, Woodmansey E, April 2010.

13 Smith & Nephew Wound Management, Data on file report reference 1208007, Visual demonstration of sequestration of Pseudomonas aeruginosa and Staphylococcus aureus in a DURAFIBER Ag dressing using confocal microscopy. Lumb H, August 2012.

14 Smith & Nephew Wound Management, Data on file report reference 1004007, Antimicrobial activity of DURAFIBER Ag and Aquacel Ag against bacteria, yeast and fungi commonly found in wounds over a 7 day period, Woodmansey E, April 2010.

15 Smith & Nephew Wound Management, Data on file report reference 1009012, Antimicrobial activity of DURAFIBER Ag against bacteria, yeast and fungi commonly found in wounds over a 7 day period, Vaughan KL, McMillan J, Lumb H and Woodmansey E, September 2010.

16 Smith & Nephew Wound Management, Data on file report reference 1004009, Assessment of the contact kill activity of DURAFIBER Ag against common wound pathogens, Woodmansey E, April 2010.

17 Smith & Nephew Wound Management, Data on file report reference 1009013, Antimicrobial activity of DURAFIBER Ag against bacteria, yeast and fungi commonly found in wounds over a 4 hour period, Vaughan KL, McMillan J, Lumb H and Woodmansey E, September 2010.

18 World Union of Wound Healing Societies (WUWHS) Principles of best practice. Wound exudate and the role of dressings. A consensus document London MED Ltd. 2007.

19 Smith & Nephew Wound Management Laboratory Report Reference DS/12/143/DOF, Intimate Contact Testing of DURAFIBER Ag, Aquacel Ag and Sorbsan Silver Flat, Dowler A, June 2012.

20 Smith & Nephew Research Centre Review Report RR WMP06290-40-01 The potential for proliferation of bacteria in wound exudate.

21 The Clinical and Physical Properties of DURAFIBER Ag, the Moist Wound Environment and the Autolytic Debridement, Myers D, July 2012.

22 Smith & Nephew Report DS.10.013 R1 02 2010 Aquacel Dressing Physical Properties.

23 Smith & Nephew Wound Management Laboratory Report Reference DS/10/060/R2, Aquacel Ag Dressing Physical Properties.

24 NHS Drug Tariff August 2012 http://www.ppa.org.uk/ppa/edit_intro.htm

25 Unit costs of health and social care, Curtis, L. PSSRU: 2010.

26 Siddiqui AR, Bernstein JM (2010).

27 DURAFIBER Technology video

28 Smith & Nephew Report DS/12/314 R December 2012 Wound Model Testing of DURAFIBER with various secondary dressings

29 DURAFIBER SMTL report 3303 Wound Dressing Testing

30 Smith & Nephew Report Development Services, Analytical Report Reference DS/10/053/R1, Wound Model Testing of DURFAIBER Ag and Aquacel Ag dressings with various secondary dressings, Dowler A, August 2010.

*In comparison with standard Aquacel dressings, excludes Aquacel Ribbon with strengthening fibre and Aquacel Extra

**In comparison with standard Aquacel Ag dressings, excludes Aquacel Ag Ribbon with strengthening fibre and Aquacel Ag Extra

Aquacel is a trademark of Convatec

TM All trademarks acknowledged

References relate to in vitro testing excluding references 3,5,18,21,24,25,26

Økonomiske fordeler

Skånsom for budsjettet 1-6

Med sin unike fiberblanding, innehar DURAFIBER bandasjer en kombinasjon av kliniske fordeler som er bra både for pasienten og for budsjettet.

Lett å fjerne i ett stykke 1-6

Minimal pleietid ved bandasjeskift24,25   DURAFIBER Dressing range
     
Effektiv væskehåndtering1-6,9 

Kan anvendes i opptil 7 dager
     
Komfortabel gelmatrise med minimal krymping1-5,19

Gir optimal bandasje-effektivitet og pasient samstemighet3,5

Vedvarende antimikrobiell aktivitet (in vitro)14,15 

>

Kan minske kostnadene i forbindelse med infeksjon5,26

Kliniske studier av DURAFIBER’s resultater er tilgjengelig ved forespørsel.

 

Example Savings Comparison

Annual budget impact of using DURAFIBER dressings for exuding wounds5,24,25

One important contributing factor to the use of resources in the treatement of exuding wounds is how long the dressing can be left in place. This in turn is dependent on a number of factors,and in particular the ability of the dressing to manage wound exudate.This model investigates the use of resources and associated costs of using gelling fibre dressings, comparing DURAFIBER with a typical existing protocol.

Results

Number of wounds on caseload

 

Time dressing left in place (Usual Care)

 

Time dressing left in place (DURAFIBER)

 

Time required to change dressing

 

Percentage of wounds switched to 6 days

200

 

3
days

 

6
days

 

20
minutes

 

50%

 

Annual use of resources Usual Care DURAFIBER Saving
Number of primary dressings 24,333 18,250  
Number of covering dressings 24,333 18,250  
Nurse time required (hours) 8,111 6,083 2,028
Nurse time (FTE’s) 4.45 3.34 1.11

 

Annual costs  Usual Care DURAFIBER Saving
Primary dressings £56,697 £38,325 £18,372
Covering dressings £92,953 £69,715 £23,238
Nurse time £551,556 £413,667 £137,889
Total £701,206 £521,707 £179,499


£179,499
cost saving

25.6% percentage
cost saving

 

Kart

DURAFIBER Cost Calculator chart

Clinical case studies of  DURAFIBER’s performance are available on request.


Referanser

1 Smith & Nephew Report DS.10.056 R1 05 2010 DURAFIBER Dressing Physical Properties.  2 DS.11.187.DOF Testing Performed as Part of DURAFIBER Photo Shoot.

3 Case Series Evaluation: The Use of DURAFIBER on Exuding Wounds. Wounds UK 2012,Vol 8, No 3.

4 Smith & Nephew Wound Management Laboratory Report Reference DS/10/060/R1, DURAFIBER Ag Dressing Physical Properties, Dowler A, September 2010.

5 Smith & Nephew Wound Management, Data on File Report Reference OR- DOF/28, A prospective, open, multicentre study to evaluate a new fibrous silver dressing in the treatment of moderate to highly exuding chronic wounds, Rafiq G, Fenton S January 2013.

6 Smith & Nephew Wound Management Laboratory Report Reference DS/12/093/DOF, Integrity Testing of DURAFIBER Ag in horse serum and ionic solution, Dowler A, April 2012.

7 Smith & Nephew Wound Management Data on File 10.040.01 April 2010 Visual demonstration of sequestration of Pseudomonas aeruginosa and Staphylococcus aureus in a DURAFIBER dressing using confocal microscopy.

8 Smith & Nephew Report DS.10.042 R1 Report of testing on lateral wicking of DURAFIBER versus AquacelTM and Kaltostat TM dressings.

9 Smith & Nephew Wound Management Laboratory Report Reference DS/12/109/DOF, Testing on Absorption of DURAFIBER Ag versus Aquacel Ag during compression, Dowler A, April 2012.

10 Smith & Nephew Wound Management Laboratory Report Reference DS/12/158/DOF, Sequestration Testing of DURAFIBER Ag, Aquacel Ag and SorbsanTM Silver Flat, Dowler A,June 2012.

11 Smith & Nephew Wound Management Laboratory Report Reference DS/12/108/DOF, Testing on lateral wicking of DURAFIBER Ag versus Aquacel Ag and MaxorbTM Extra Ag dressings, Dowler A, April 2012.

12 Smith & Nephew Research Centre Review Report, The potential for proliferation of bacteria in wound exudate, Report Reference RR-WMP06290-40-01, Woodmansey E, April 2010.

13 Smith & Nephew Wound Management, Data on file report reference 1208007, Visual demonstration of sequestration of Pseudomonas aeruginosa and Staphylococcus aureus in a DURAFIBER Ag dressing using confocal microscopy. Lumb H, August 2012.

14 Smith & Nephew Wound Management, Data on file report reference 1004007, Antimicrobial activity of DURAFIBER Ag and Aquacel Ag against bacteria, yeast and fungi commonly found in wounds over a 7 day period, Woodmansey E, April 2010.

15 Smith & Nephew Wound Management, Data on file report reference 1009012, Antimicrobial activity of DURAFIBER Ag against bacteria, yeast and fungi commonly found in wounds over a 7 day period, Vaughan KL, McMillan J, Lumb H and Woodmansey E, September 2010.

16 Smith & Nephew Wound Management, Data on file report reference 1004009, Assessment of the contact kill activity of DURAFIBER Ag against common wound pathogens, Woodmansey E, April 2010.

17 Smith & Nephew Wound Management, Data on file report reference 1009013, Antimicrobial activity of DURAFIBER Ag against bacteria, yeast and fungi commonly found in wounds over a 4 hour period, Vaughan KL, McMillan J, Lumb H and Woodmansey E, September 2010.

18 World Union of Wound Healing Societies (WUWHS) Principles of best practice. Wound exudate and the role of dressings. A consensus document London MED Ltd. 2007.

19 Smith & Nephew Wound Management Laboratory Report Reference DS/12/143/DOF, Intimate Contact Testing of DURAFIBER Ag, Aquacel Ag and Sorbsan Silver Flat, Dowler A, June 2012.

20 Smith & Nephew Research Centre Review Report RR WMP06290-40-01 The potential for proliferation of bacteria in wound exudate.

21 The Clinical and Physical Properties of DURAFIBER Ag, the Moist Wound Environment and the Autolytic Debridement, Myers D, July 2012.

22 Smith & Nephew Report DS.10.013 R1 02 2010 Aquacel Dressing Physical Properties.

23 Smith & Nephew Wound Management Laboratory Report Reference DS/10/060/R2, Aquacel Ag Dressing Physical Properties.

24 NHS Drug Tariff August 2012 http://www.ppa.org.uk/ppa/edit_intro.htm

25 Unit costs of health and social care, Curtis, L. PSSRU: 2010.

26 Siddiqui AR, Bernstein JM (2010).

27 DURAFIBER Technology video

28 Smith & Nephew Report DS/12/314 R December 2012 Wound Model Testing of DURAFIBER with various secondary dressings

29 DURAFIBER SMTL report 3303 Wound Dressing Testing

30 Smith & Nephew Report Development Services, Analytical Report Reference DS/10/053/R1, Wound Model Testing of DURFAIBER Ag and Aquacel Ag dressings with various secondary dressings, Dowler A, August 2010.

*In comparison with standard Aquacel dressings, excludes Aquacel Ribbon with strengthening fibre and Aquacel Extra

**In comparison with standard Aquacel Ag dressings, excludes Aquacel Ag Ribbon with strengthening fibre and Aquacel Ag Extra

Aquacel is a trademark of Convatec

TM All trademarks acknowledged

 

References relate to in vitro testing excluding references 3,5,18,21,24,25,26

Spørsmål og svar

DURAFIBEROfte stilte spørsmål om DURAFIBER bandasjer

Hvilke typer sår kan DURAFIBER brukes på?

DURAFIBER kan brukes til å behandle kroniske og akutte dype, delvis dype eller overflatiske granulerende sår, som: leggsår, trykksår, diabetessår, delvis dype brannsår, donorsteder, operasjons- og traumesår, sår som leges ved sekundær metode, sår som er utsatt for blødning etter rensing. NB DURAFIBER er ikke utviklet til bruk som kirurgisk svamp.

Hvor ofte må DURAFIBER skiftes?

DURAFIBER kan sitte på plass i opptil 7 dager, da den høytabsorberende kapasiteten bidrar til å gi effektiv væskekontroll. Den kan alternativt skiftes når det foreligger klinisk indikasjon for det, f.eks. hvis det er mye sårvæske eller lekkasje.

Hvilken størrelse finnes DURAFIBER i?

DURAFIBER finnes i følgende størrelser - a) firkant: 5x5 cm, 10x10 cm, 15x15 cm, b) rektangel: 4x10 cm, 4x20 cm, 4x30 cm og c) bånd: 2x45 cm

Hvordan steriliseres DURAFIBER?

DURAFIBER er gammabestrålt.

Hvordan pakkes DURAFIBER?

DURAFIBER pakkes i papirpolyemballasje

Hvordan er konstruksjonen av DURAFIBER forskjellig fra Aquacel™*?

Når det gjelder sammensetningen av de to produktene, består både DURAFIBER og Aquacel av 100 % cellulosebaserte fibrer. Forskjellen mellom de to produktene ligger i måten disse fibrene endres på for å gi en bandasje med geldannende og absorberende egenskaper. Convatec endrer de cellulosebaserte fibrene ved karboksymetylering for å gi en karboksymetylcellulose (CMC)-basert bandasje som kan forvandles til en sårvæske-absorberende gel.
Convatec har immaterielle rettigheter som forhindrer at andre produsenter bruker CMC-fibre i sårbandasjer av denne typen. Med DURAFIBER har Smith & Nephew utviklet en annen måte å endre de cellulosebaserte fibrene på, nemlig etylsulfonering. Denne prosessen produserer en cellulose-etylsulfonat (CES)-basert bandasje som også er i stand til å forvandles til en gel og absorbere sårvæske.

Virker DURAFIBER på samme måte som Aquacel*?

DURAFIBER er en uvevd, geldannende fiberbandasje som er utviklet for å gi ytelse som kan sammenlignes med Aquacel, med det resultatet at det dannes en myk, bindekraftig gel ved kontakt med væske; den føyer seg etter sårbunnen; låser inne absorbert væske og bakterier og forhindrer spredning av væske til siden for å minimere risikoen for maserasjon ved sårkantene 1,2,7,8

Hvilke fordeler har DURAFIBER, sammenlignet med Aquacel?

Sammenlignet med Aquacel er DURAFIBER også utviklet for å tilby mer enn tre og en halv ganger større styrke i våt tilstand - gelstyrken er viktig for at det skal være lett å fjerne bandasjen hel 1,2,22, over 30 % bedre absorberingsevne - bandasjens absorberingsevne er viktig for å sikre effektiv væskekontroll 1,2,22 og 43 % mindre krymping av bandasjen - minimal krymping er viktig for å oppnå bedre dekke av sårbunnen 1,2,22

Hvilken informasjon viser ytelsen av produktet kontra Aquacel*?

De fysiske egenskapene til DURAFIBER og standard Aquacel er blitt sammenlignet in-vitro av Smith & Nephew og av en uavhengig tester, SMTL. Resultatene viser tydelig at de to bandasjene har lignende ytelsesegenskaper, uavhengig av forskjellene i den kjemiske endringsprosessen 1,2,22. Disse resultatene viser også at DURAFIBER har større våtfasthet 1,2,22,29, større absorberingsevne 1,2,22 og at bandasjen krymper mindre 1,2,22 sammenlignet med standard Aquacel.

DURAFIBER AgOfte stilte spørsmål om DURAFIBER Ag bandasjer

Hvilke typer sår kan DURAFIBER Ag brukes på?

DURAFIBER kan brukes til å behandle kroniske og akutte dype, delvis dype eller overflatiske granulerende, væskende sår. For eksempel: leggsår, trykksår, diabetessår, operasjonssår, traumesår, donorsteder, delvis dype sår, innvendige sår, fistelsår, sår som behandles med sekundær metode, og sår som er utsatt for blødning (for eksempel renset kirurgisk eller mekanisk).

Hvor ofte må DURAFIBER Ag skiftes?

DURAFIBER Ag kan sitte på plass i opptil 7 dager, da dens høytabsorberende kapasitet bidrar til effektiv væskekontroll. Den kan alternativt skiftes når det foreligger klinisk indikasjon for det, for eksempel hvis det er mye sårvæske eller lekkasje.

Hvilken størrelse finnes DURAFIBER Ag i?

DURAFIBER finnes i følgende størrelser - a) firkant: 5x5 cm, 10x10 cm, 15x15 cm, b) rektangel: 20x30 cm 4x10 cm, 4x20 cm, 4x30 cm og c) bånd: 2x45 cm

Hvordan steriliseres DURAFIBER Ag?

DURAFIBER er gammabestrålt.

Hvordan pakkes DURAFIBER Ag?

DURAFIBER er pakket i folie

Hvilke fordeler har DURAFIBER Ag, sammenlignet med Aquacel Ag**?

Sammenlignet med Aquacel Ag er DURAFIBER Ag også utviklet for å tilby mer enn tre og en halv ganger bedre styrke i våt tilstand - gelstyrken er viktig for at det skal være lett å fjerne bandasjen hel, over 17 prosent bedre absorberingsevne - bandasjens absorberingsevne er viktig for å sikre effektiv væskekontroll og 43 prosent mindre krymping av bandasje- minimal krymping er viktig for å oppnå bedre dekke av sårbunnen

Hvilken informasjon viser ytelsen (in vitro) av produktet kontra Aquacel Ag**?

De fysiske egenskapene til DURAFIBER Ag og standard Aquacel Ag er blitt sammenlignet (in vitro) av Smith & Nephew. Resultatene viser tydelig at de to bandasjene har lignende ytelsesegenskaper, uavhengig av forskjellige i den kjemiske endringsprosessen. Disse resultatene viser også at DURAFIBER Ag har større styrke i våt tilstand, større absorberingsevne og at bandasjen krymper mindre sammenlignet med standard Aquacel Ag. DURAFIBER Ag har den samme antimikrobielle ytelsen som Aquacel Ag

Hvilken type sølv inneholder DURAFIBER Ag?

Sølvklorid finnes i bandasjen, som oppløses i sølvioner som frigis i såret.

Referanser

1 Smith & Nephew Report DS.10.056 R1 05 2010 DURAFIBER Dressing Physical Properties.

2 DS.11.187.DOF Testing Performed as Part of DURAFIBER Photo Shoot.

3 Case Series Evaluation: The Use of DURAFIBER on Exuding Wounds. Wounds UK 2012,Vol 8, No 3.

4 Smith & Nephew Wound Management Laboratory Report Reference DS/10/060/R1, DURAFIBER Ag Dressing Physical Properties, Dowler A, September 2010.

5 Smith & Nephew Wound Management, Data on File Report Reference OR- DOF/28, A prospective, open, multicentre study to evaluate a new fibrous silver dressing in the treatment of moderate to highly exuding chronic wounds, Rafiq G, Fenton S January 2013.

6 Smith & Nephew Wound Management Laboratory Report Reference DS/12/093/DOF, Integrity Testing of DURAFIBER Ag in horse serum and ionic solution, Dowler A, April 2012.

7 Smith & Nephew Wound Management Data on File 10.040.01 April 2010 Visual demonstration of sequestration of Pseudomonas aeruginosa and Staphylococcus aureus in a DURAFIBER dressing using confocal microscopy.

8 Smith & Nephew Report DS.10.042 R1 Report of testing on lateral wicking of DURAFIBER versus AquacelTM and Kaltostat TM dressings.

9 Smith & Nephew Wound Management Laboratory Report Reference DS/12/109/DOF, Testing on Absorption of DURAFIBER Ag versus Aquacel Ag during compression, Dowler A, April 2012.

10 Smith & Nephew Wound Management Laboratory Report Reference DS/12/158/DOF, Sequestration Testing of DURAFIBER Ag, Aquacel Ag and SorbsanTM Silver Flat, Dowler A,June 2012.

11 Smith & Nephew Wound Management Laboratory Report Reference DS/12/108/DOF, Testing on lateral wicking of DURAFIBER Ag versus Aquacel Ag and MaxorbTM Extra Ag dressings, Dowler A, April 2012.

12 Smith & Nephew Research Centre Review Report, The potential for proliferation of bacteria in wound exudate, Report Reference RR-WMP06290-40-01, Woodmansey E, April 2010.

13 Smith & Nephew Wound Management, Data on file report reference 1208007, Visual demonstration of sequestration of Pseudomonas aeruginosa and Staphylococcus aureus in a DURAFIBER Ag dressing using confocal microscopy. Lumb H, August 2012.

14 Smith & Nephew Wound Management, Data on file report reference 1004007, Antimicrobial activity of DURAFIBER Ag and Aquacel Ag against bacteria, yeast and fungi commonly found in wounds over a 7 day period, Woodmansey E, April 2010.

15 Smith & Nephew Wound Management, Data on file report reference 1009012, Antimicrobial activity of DURAFIBER Ag against bacteria, yeast and fungi commonly found in wounds over a 7 day period, Vaughan KL, McMillan J, Lumb H and Woodmansey E, September 2010.

16 Smith & Nephew Wound Management, Data on file report reference 1004009, Assessment of the contact kill activity of DURAFIBER Ag against common wound pathogens, Woodmansey E, April 2010.

17 Smith & Nephew Wound Management, Data on file report reference 1009013, Antimicrobial activity of DURAFIBER Ag against bacteria, yeast and fungi commonly found in wounds over a 4 hour period, Vaughan KL, McMillan J, Lumb H and Woodmansey E, September 2010.

18 World Union of Wound Healing Societies (WUWHS) Principles of best practice. Wound exudate and the role of dressings. A consensus document London MED Ltd. 2007.

19 Smith & Nephew Wound Management Laboratory Report Reference DS/12/143/DOF, Intimate Contact Testing of DURAFIBER Ag, Aquacel Ag and Sorbsan Silver Flat, Dowler A, June 2012.

20 Smith & Nephew Research Centre Review Report RR WMP06290-40-01 The potential for proliferation of bacteria in wound exudate.

21 The Clinical and Physical Properties of DURAFIBER Ag, the Moist Wound Environment and the Autolytic Debridement, Myers D, July 2012.

22 Smith & Nephew Report DS.10.013 R1 02 2010 Aquacel Dressing Physical Properties.

23 Smith & Nephew Wound Management Laboratory Report Reference DS/10/060/R2, Aquacel Ag Dressing Physical Properties.

24 NHS Drug Tariff August 2012 http://www.ppa.org.uk/ppa/edit_intro.htm

25 Unit costs of health and social care, Curtis, L. PSSRU: 2010.

26 Siddiqui AR, Bernstein JM (2010).

27 DURAFIBER Technology video

28 Smith & Nephew Report DS/12/314 R December 2012 Wound Model Testing of DURAFIBER with various secondary dressings

29 DURAFIBER SMTL report 3303 Wound Dressing Testing

30 Smith & Nephew Report Development Services, Analytical Report Reference DS/10/053/R1, Wound Model Testing of DURFAIBER Ag and Aquacel Ag dressings with various secondary dressings, Dowler A, August 2010.

*In comparison with standard Aquacel dressings, excludes Aquacel Ribbon with strengthening fibre and Aquacel Extra

**In comparison with standard Aquacel Ag dressings, excludes Aquacel Ag Ribbon with strengthening fibre and Aquacel Ag Extra

Aquacel is a trademark of Convatec

TM All trademarks acknowledged

References relate to in vitro testing excluding references 3,5,18,21,24,25,26

DURAFIBER

En ny generasjon sterke, geldannende fiberbandasjer som enkelt kan fjernes i ett stykke.

LES MER

DURAFIBER Ag

En absorberende, uvevd antimikrobiell sølvbandasje.

LES MER

Contact Us

DURAFIBER RangeDiscover more about the DURAFIBER range Enquiry Form

Get in Touch